Managing Life-Threatening Bleeding in Patient with High Plasma Concentration of Dabigatran with Thromboelastogram, Idarucizumab and Renal Replacement Therapy

Case Report

Austin Crit Care Case Rep. 2021; 5(2): 1024.

Managing Life-Threatening Bleeding in Patient with High Plasma Concentration of Dabigatran with Thromboelastogram, Idarucizumab and Renal Replacement Therapy

Ego A*, Lheureux O and Creteur Jacques J

Department of Intensive Care, University Libre de Bruxelles (ULB), Belgium

*Corresponding author: Amedee Ego, Department of Intensive Care, Erasme Hospital, University Libre de Bruxelles (ULB), Route de Lennik, 808, 1070 Brussels, Belgium

Received: January 23, 2021; Accepted: February 23, 2021; Published: March 02, 2021

Abstract

We present a case of patient with spontaneous cardiac tamponade related to a very high 2-plasma concentration of dabigatran, an oral direct-acting thrombin inhibitor. By selectively inhibiting thrombin alone, dabigatran may have antithrombotic efficacy while preserving some other hemostatic mechanisms in the coagulation system and thus potentially mitigating the risk of bleeding. Nonetheless, serious bleeding can occur with dabigatran. We illustrate the management of this life threatening hemorrhagic complication by the combination of cardiac surgery, antagonization of the anticoagulant effect (using Idarucizumab, an humanized monoclonal antibody fragment and continuous renal replacement therapy), and monitoring of the effects on coagulation by thromboelastogram.

Introduction

Dabigatran is a new oral direct-acting thrombin inhibitor effective in the prevention of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and stroke in patients with Atrial Fibrillation (AF). Dabigatran has interesting pharmacokinetic and pharmacodynamic properties: non-vitamin dependent, metabolism independent of liver function, and with a few drug interferences [1]. By selectively inhibiting thrombin alone, dabigatran may have antithrombotic efficacy while preserving some other hemostatic mechanisms in the coagulation system and thus potentially mitigating the risk of bleeding. These properties associated with the uselessness of biological monitoring explain the success of new oral anticoagulants.

Compared to warfarin, treatment with dabigatran (150 mg twice daily) for AF and for the treatment of PE and DVT was associated with a higher rate of gastrointestinal bleeding and a lower rate of intracranial bleeding [1-3]. Nonetheless, serious bleeding can occur with dabigatran. Dabigatran is mainly (80%) excreted by the kidneys (its serum half-life is between 12 and 17 hours), making its use more limited in cases of renal failure [1]. In case of severe and active bleeding, the anticoagulant effect cannot be reversed with vitamin K, unlike warfarin. Idarucizumab is a humanized monoclonal antibody fragment that has been developed as a specific reversal agent for dabigatran. Idarucizumab selectively and exclusively binds dabigatran with an affinity ≈350-fold higher than the affinity of dabigatran for thrombin and neutralizes its anticoagulant effect immediately, especially in case of uncontrollable bleeding [4]. We present a case of an 84-year-old patient with spontaneous tamponade in a context of high plasma concentration of dabigatran, who required idarucizumab, four-factor prothrombin complex concentrates and continuous renal replacement therapy to control this life-threatening situation.

Case Presentation

An 84-year-old male with history of hypertension, AF, hyperlipidemia, severe arteriopathy, usually taking dabigatran (150mg twice daily), ACE-inhibitor with hydrochlorothiazide, and ezetimibe, presented to the emergency department for asthenia and dyspnea worsening since several days. Physical examination and vital parameters showed poor skin perfusion, lethargy, jugular turgor, tachycardia with paradoxical pulse, and arterial hypotension. Cardiac tamponade characterized by a circumferential pericardial effusion with compression of the right cavities was diagnosed by the use of cardiac ultrasound. Admission blood tests showed lactic acidosis (3.6mEq/L), acute renal failure KDIGO I (creatinine: 208.5μmol/L, uremia: 39.2mmol/L) and a significant alteration of standard coagulation tests: Activated Partial Thromboplastin Time (APTT) at 127s (normal range from 30 to 40 s) and Prothrombin Time (PT) at 143s (normal range from 11 to 13, 5s). Fibrinogen concentration and platelets count were in the normal ranges. The plasma concentration of dabigatran at admission was 368ng/mL. The patient reported no medication error.

To allow a sub-xyphoid pericardial puncture in order to evacuate the pericardial effusion, a reversion of dabigatran was quickly started by the administration of 50U/Kg of four-factor prothrombin complex concentrates (COFACT®) and with a 5g dose of idarucizumab. 200 cc of bloody liquid were drained under ultrasound guidance, resulting in a rapid resolution of the shock. However, no drain could be left in place due to an excessively thick pericardium. Thereafter, cardiac ultrasound examinations showed a very gradual recurrence of pericardial without compression of cavities. Despite the administration of a first dose of idarucizumab, the plasma level of dabigatran was still higher than the initial concentration (490ng/mL). Standard coagulation tests Remained Altered and Thromboelastogram (ROTEM®) showed a significant extended clotting time. Renal function deteriorated to a grade KDIGO III (creatinine: 586.9μmol/L, uremia 91.7mmol/L). In this context, Renal Replacement Therapy (RRT) by continuous venovenous hemodiafiltration (blood flow: 180ml/min; dialysate flow: 2000ml/h; no fluid withdrawal) was started in order to increase the clearance of dabigatran. In the following hours, successive biological analyzes showed a significant decrease in the plasma concentration of dabigatran as well as a progressive resolution of the coagulopathy on all tests (Figure 1 and Table 1).

Citation:Ego A, Lheureux O and Creteur Jacques J. Managing Life-Threatening Bleeding in Patient with High Plasma Concentration of Dabigatran with Thromboelastogram, Idarucizumab and Renal Replacement Therapy. Austin Crit Care Case Rep. 2021; 5(2): 1024.